Edition:
India

Morphosys Says Its Licensing Partner GSK Starts Phase 3 Otilimab Programme


Wednesday, 3 Jul 2019 

July 3 (Reuters) - MorphoSys AG ::DGAP-NEWS: MORPHOSYS'S LICENSING PARTNER GSK INITIATES PHASE 3 CLINICAL PROGRAM WITH OTILIMAB (MOR103/GSK3196165) IN RHEUMATOID ARTHRITIS; MORPHOSYS UPDATES ITS FINANCIAL GUIDANCE FOR 2019.ANNOUNCES THAT ITS LICENSING PARTNER GSK REPORTED IN A PRESS RELEASE EARLIER TODAY START OF A PHASE 3 CLINICAL DEVELOPMENT PROGRAM WITH OTILIMAB IN RHEUMATOID ARTHRITIS. 

Company Quote

99.95
0.3 +0.30%
9:05pm IST